Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
5 January 2016

Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

12 May 2025

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

8 May 2025

ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

24 April 2025

ORYZON Raises €30 Million in Capital Increase

21 April 2025

ORYZON continues to strengthen its patent portfolio for vafidemstat

15 April 2025

ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

1-3 April 2025

Van Lanschot Kempen Life Sciences Conference

Van Lanschot Kempen

Amsterdam

Netherlands

17-19 March 2025

BIO-Europe Spring 2025

Allianz MiCo, Milan

MI

Italy

14 March 2025

ORYZON to provide corporate progress updates at several events in March-April

5 March 2025

Oryzon announces publication of study on Phelan-McDermid Syndrome (PMS) patients, a form of autism, paving the way for a novel personalized medicine approach with vafidemstat

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel